Background

Applicant Information

(Carefully read the instructions before completing this form)

1. Applicant Information

Your User Profile information appears below however this section should indicate where the research described within this proposal will take place (change as necessary). NOTE: Your User Profile is always considered your current mailing address. The address listed here will be used to advise you of the outcome of this competition only.

a. Applicant Name — Title ○ Dr ○ Mr ○ Ms ○ Prof
b. Institution
c. Department
d. Address 1
e. Address 2
f. Address 3
g. Address 4
h. Country
i. City — Province — Postal Code
j. Phone — Ext — Fax
k. e-Mail Address
l. Designation

2. Project Information

The title entered when the application was created is indicated. Please avoid typing in ALL CAPS. In addition, ensure the end date of your project is updated.

a. Project Title
b. Is Financial Institution the same as the Research Institution? (Please select Yes or No) ○ Yes ○ No
c. If No, provide Financial Institution name
d. Project Start Date — End Date
e. Amount of Funds Requested — Project Cost
f. Type of application: Note: maximum 1 application allowed per PI
   ○ Initial Application
g. Indicate the number of years of support requested (up to 3)
h. Is this application being submitted in French? (Note that all review panels are conducted in English.) ○ Yes ○ No

3. Contact Information

Enter any Co-Principal Investigator, Co-Applicant, Additional Author, People affected by cancer, Implementer/Decision-maker and Collaborator information as applicable to your application. Provide full addresses, including department name/affiliation for each participant. Use the lookup feature and enter their e-mail address in the field provided as the search criteria. The form will be auto-populated with their contact information as it appears in their user profile. If they do not have a profile, enter the details as required. CVs, letters of support and collaboration are not required at the abstract registration stage.
NOTE: Changes to the applicant list after the abstract registration deadline are permitted, but must be provided to the CCS as they are determined.

a. Additional Author
Name
Title
Institution
Department
Address 1
Address 2
Address 3
Address 4
Country
City Province Postal Code
Telephone Fax
E-Mail Address

b. Co-Applicant
Name
Title
Institution
Department
Address 1
Address 2
Address 3
Address 4
Country
City Province Postal Code
Telephone Fax
E-Mail Address

c. Collaborator
Name
Title
Institution
Department
Address 1
Address 2
Address 3
Address 4
Country
City Province Postal Code
Telephone Fax
E-Mail Address

d. Co-Principal Investigator
Name
Title

Institution
Department
Address 1
Address 2
Address 3
Address 4
Country
City Province Postal Code
Telephone Fax
E-Mail Address

e. Financial Officer
Name
Title
Institution
Department
Address 1
Address 2
Address 3
Address 4
Country
City Province Postal Code
Telephone Fax
E-Mail Address

f. Implementer/Decision-maker
Name
Title
Institution
Department
Address 1
Address 2
Address 3
Address 4
Country
City Province Postal Code
Telephone Fax
E-Mail Address

g. People affected by cancer
Name
Title
Institution
Department
Address 1
Address 2
Address 3
Address 4
Country
City Province Postal Code
Telephone Fax
E-Mail Address

Applicant info

4. Principal investigator CV

Attach an up-to-date, abbreviated version of your CV (NIH-style biosketch) in PDF format. Consult the Application Guide for complete instructions, including the required format.
NOTE: For the file name, please use the following format:[lastname_firstname-CV].
CCS is not a member organization of the Common CV Network, therefore the Common CV should not be used due to Common CV use restrictions.

5. Justification for career interruptions

Briefly, describe any career interruptions or delays that may have impacted your academic career and research productivity. Please include the start and end dates of each period described (yyyy/mm). FOR COVID-related interruption, simply state COVID-19 and indicate 2020/02 - 2021/09 (20 months). If not applicable, please indicate this in the form.

6. Application and Career stage

This section is mandatory and plays no part in the review or funding of an application. The data is used for statistical and communication purposes only. To account for impacts of the COVID-19 pandemic on the research community, applicants are asked to subtract 18 months (covering the period of March 2020 – Sept 2021) when calculating career stage.

Please indicate below if this is:

Your first application for a research grant to the Canadian Cancer Society	○ Yes	○ No
Your first application for a research grant specifically in the area of cancer research	○ Yes	○ No
Your first application for a research grant as an independent investigator	○ Yes	○ No

Please indicate your current career stage (please select one of the three options) - click “Show Instructions” for guidance on how to account for COVID-19-dependent delays when calculating career stage:

- ○ New/early career investigator: Any applicant who, at the time of registration, assumed his/her first independent academic position (e.g., faculty appointment) no more than 5 years ago (60 months).
- ○ Mid-career investigator: Any applicant who, at the time of registration, assumed his/her first independent academic position (e.g., faculty appointment) 5-15 years ago.
- ○ Senior investigator: Any applicant who, at the time of registration, assumed his/her first independent academic position (e.g., faculty appointment) more than 15 years ago.

Certificates

7. Certificates required

7.a. Biohazard/Biosafety

Indicate if certificates will be required. Certificates will be requested at the time of funding.

a. Does your project require a biohazard certificate? ○ Yes ○ No

b. If yes, list the name of institution(s) from where the certificate(s) will be obtained, what project stage they will be required (e.g. for Aim 2), and when you expect the certificate to be provided to CCS (Date).

Institution	Project Stage	Date (mm/yyyy)

7.b. Animal care

Indicate if certificates will be required. Certificates will be requested at the time of funding.

a. Does your project require animal care certificates? ○ Yes ○ No

b. If yes, list the name of institution(s) from where the certificate(s) will be obtained, what project stage they will be required (e.g. for Aim 2), and when you expect the certificate to be provided to CCS (Date).

Institutions	Project stage	Date (mm/yyyy)

7.c. Ethics

Indicate if certificates will be required. Certificates will be requested at the time of funding.

a. Does your project require ethics certificates? ○ Yes ○ No

b. If yes, list the name of institution(s) from where the certificate(s) will be obtained, what project stage they will be required (e.g. for Aim 2), and when you expect the certificate to be provided to CCS (Date).

Institution	Project stage	Date (mm/yyyy)

7.d. Human samples

Indicate if human samples will be used. Appropriate evidence demonstrating that the PI has registered/enrolled for bio-specimen collection with a quality assurance program will be requested at the time of funding. This applies equally to all prospective (new) bio-specimens used in the CCS-funded research that will be collected and/or all retrospective (old) bio-specimens used in the CCS-funded research that have previously been collected and will come from a biobank(s).

a. Does your project involve the use of human samples? ○ Yes ○ No

b. Please list details.

List of biobanks

8.a. Human embryonic stem cells involvement

Any applicant who proposes the creation or use of human embryonic stem cells, or proposes any research that would fall under the federal legislation or the CIHR Guidelines must clearly indicate this fact in the section provided, and must disclose all relevant details in the proposal.

Does the proposal involve the use or creation of human embryonic stem cells? (If yes, contact the CCS) ○ Yes ○ No

If yes, is the research reviewed under the auspices of the local ethics review board? (Do not answer this if the answer above is No)

8.b. Status of SCOC approval for each institution

In the space provided, indicate the status of Stem Cell Oversight Committee (SCOC) approval for each institution. Applicants are reminded to disclose all relevant details related to the hESC work in the proposal. (maximum 1250 characters). Do not complete this section if your project doesn't involve hESCs.

Public summary

9. Public summary

Please provide a plain language summary (abstract) of your project that will be shared with our patient/survivor/caregiver reviewers and potentially with our donors and other stakeholders. Note that this summary should be understandable by someone who does not have a scientific background and should not contain confidential information.

In your summary, please address the following questions:

- What is the goal/purpose of your project? What need does it address?
- What are you proposing to do?
- Why is this work important? How will it impact people affected by cancer?

Maximum 2000 characters, including spaces. Note that the character count may be different when copying text from Word due to formatting.

Abstract

10. Scientific abstract

Provide a detailed summary of your research project describing the issue to be addressed, the rationale for the population of focus and the chosen approach to advance cancer-related health equity, the overall aims/ objectives of the proposed research, a brief description of the methodology to be used, and anticipated outcomes of the project. Include language that speaks to the co-creation approach used in developing the research plan. Maximum of 4200 characters, including spaces. Character count may be different when copying text from Word due to formatting.

11. Keywords

Provide up to a maximum of ten specific keywords or descriptive terms that best describe the focus and approach of your project. NOTE: Enter one keyword or term per line.

Keywords

12. Abstract Changes

Indicate if significant modifications have been made since the abstract registration. If you answer yes, please advise CCS research staff (research@cancer.ca). Substantive changes that significantly alter the overall goals and aims of the proposal relative to the abstract registration are not permitted.

○ Yes ○ No

Non-confidential scientific abstract

13. Non-confidential scientific abstract

Please include a duplicate of your scientific abstract – with proprietary information removed. This abstract may be shared with potential donors and CCS funding partners and stakeholders when relevant. Your abstract should not exceed 4200 characters (including spaces), or roughly one full page, single spaced. Note that the character count may be different when copying text from Word due to formatting.

Relevance Statement

14. Relevance Statement

Provide a relevance statement that clearly explains the rationale for the population of focus (including sub-groups and intersectionality of determinants) and the chosen approach to advance cancer-related health equity. Meaningful, integral involvement of relevant representatives in identifying the proposed topic, study design and methods, evaluation/analysis and dissemination plans must be evident. Implications and proposed methods for achieving outcomes should be described.
Please note that this section will be used by patient/survivor/caregiver reviewers to evaluate the relevance and overall impact of the proposed work. The relevance statement should be written in non-technical language, and not exceed 2100 characters, or roughly half page, including spaces. Note that character count may be different when copying text from Word due to formatting.

Proposal

15. Proposal

Provide a detailed proposal of the work to be performed, including the following points (not exceeding 21,000 characters, refer to program guide for details of requirements): goal and aims of the project; experimental design, methods, and analysis, and research team members. Provide a list of references cited within the proposal. A standard reference style is recommended (e.g. first author, article title, journal title, date of publication, volume, issue, location (pagination)).
Format:

- Your proposal should not exceed 21,000 characters (including spaces), or roughly 5 full pages, single spaced (not including references).
- Upload the proposal (including references) in EGrAMS as a single pdf not larger than 5MB
- Figures, tables, charts and their associated legends must NOT be embedded in the text. For information regarding accompanying figures, tables, charts and associated legends, see section 17 – Tables, graphs, charts and associated legends.
- Abbreviations must be initially explained within the proposal. A list of abbreviations, if included, counts towards the 21,000-character limit.

16. Tables, graphs, charts and associated legends

OPTIONAL: Attach and appropriately label figures, graphs, charts and legends in PDF format (maximum of 2 pages and 5 MB total) NOTE: For the file name, please use the following format: [lastname_firstname-figures].

17. Sex, gender and diversity

17.a. Sex, gender and diversity considerations

Recognizing the variable impacts of cancer on different populations and demographics within Canadian society, CCS expects that sex, gender and diversity dimensions (plus other intersectionalities (SGBA+)) will be factored into research design, analysis and dissemination of findings. Please provide a response for each question, and we urge that you consider and embed these dimensions into your proposal, when applicable.

Is sex, as a biological variable, taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings?	○ Yes	○ No
Is gender, as a sociocultural factor, taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings?	○ Yes	○ No
Are diversity considerations (e.g. conditions, expressions and experiences of different groups identified by age, education, sexual orientation, parental status/responsibility, immigration status, Indigenous status, religion, disability, language, race, place of origin, ethnicity, culture, socio-economic status and other attributes) taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings?	○ Yes	○ No

17.b. Sex, gender and diversity considerations

Describe how sex and/or gender and/or diversity dimensions (plus other intersectionalities (SGBA+)) will be considered in your research proposal. If you select 'No' for one or more questions in section 18a., explain why sex and/or gender and/or diversity are not applicable in your research proposal.
Your response must not exceed 4200 characters. Note that the character count may be different when copying text from Word due to formatting.

18. Products/Implementation Plan

Describe the products anticipated to result from this program (including publications, tools, tactics, frameworks, educational materials, etc.), including details of ownership. Include a clear knowledge translation, dissemination and implementation plan for how the results will be communicated with relevant audiences along with intended use. Include dissemination methodology/tactics to stakeholder communities.
Your response must not exceed 4200 characters, or roughly one page, single spaced. Note that the character count may be different when copying text from Word due to formatting. To insert special characters, you must use Alt codes or the special character tool in EGrAMS and not Symbol font.

19. Research team contributions

List each research team member (both those named on the grant as a Participant and any others not named), and indicate the % of the project work to be completed by each individual. The total % should add to 100, do not add a '%' sign in the '% of work' field. Research team member contributions can be indicated to 1 decimal place, as appropriate.

Participant	Percent of the project work

20. Terms of Reference

A detailed Terms of Reference for all members of the team is required as part of the application process. The template provided is recommended, but not mandatory for use. Teams may opt to utilize other appropriate templates.
Template can be found at
https://cdn.cancer.ca/-/media/files/research/for-researchers/documentation-for-applicants/tor_template_2022.docx
Note that Term of Reference may be revised throughout the duration of the project and need not be ‘final’ but must be reviewed and agreed to by all team members.
Please upload a PDF document to EGrAMS, not to exceed 5 MB in size.

21. Appendices

OPTIONAL: Note that all essential information must be included in the proposal and that reviewers are not required to read the material in the appendices. Attachments must be in PDF format only and can not exceed 10MB per attachment. NOTE: For the file name, please use the following format: [lastname_firstname-appendix1].

22. Disclosure of commercial or conflict of interest related to this application

If any of the named investigators have a financial interest in any commercial venture whose business activities are related to the subject matter of this grant application, the nature of that interest must be disclosed and a description of how conflict of interest (perceived or real) , if any, will be managed should be provided. Please describe the nature of the relationship or material interest, the business activities of the company in question, and how those activities relate, if at all, to the grant application.

a. Do applicants have any commercial or conflict of interest (perceived or real) to declare? ○ Yes ○ No

b. If Yes, please provide a description of the commercial or conflict of interest and how it will be managed.

c. Is there any Intellectual Property which has been filed that is directly related to the technology or project, or materials or reagents used therein? ○ Yes ○ No

d. If Yes, please describe, including ownership and/or assignment.

Budget

Description		2022	2023	2024	Total
DIRECT EXPENSES					
Program Expenses					
1	**Supplies and Expenses**				
2	**Salaries and Wages**				
Total Program Expenses		0.00	0.00	0.00	0.00
Equipment					
1	**Permanent Equipment**				
Total Equipment		0.00	0.00	0.00	0.00
TOTAL DIRECT EXPENSES		0.00	0.00	0.00	0.00
TOTAL EXPENDITURES		0.00	0.00	0.00	0.00

Description	2022	2023	2024	Total
Program Expenses				
Supplies and Expenses	0.00	0.00	0.00	0.00
Salaries and Wages	0.00	0.00	0.00	0.00
Total for Program Expenses	**0.00**	**0.00**	**0.00**	**0.00**
Permanent Equipment	0.00	0.00	0.00	0.00
TOTALS	**0.00**	**0.00**	**0.00**	**0.00**

Other funding

25. Summary of other funding applied for and received

List all grants currently being applied for, pending, about to be submitted and all grants received, for the entire period covered by this application, for the Principal Investigator and each Co-Principal Investigator. Your documentation should include a list followed by the abstracts/summaries, as submitted in the original application for funding, for all grants/applications listed and should be submitted in PDF format. For pending grant applications with similar titles, please include a statement explaining overlap, or lack thereof. Consult the Application Guide for complete instructions, including the correct format. If there are no pending grants to list, indicate by including N/A in the Pending grants section. Applications with missing other funding information or abstracts will be considered incomplete.
NOTE: For the file name, please use the following format: [lastname_firstname-other_funding]

26. Other funding confirmation

☐ The applicants confirm that the attached list contains all required information, including the percentage overlap for each grant and the abstracts as submitted in the original application for funding, as described in the Application Guide.

Review panel

27. Panel

Assigned panel:

Health Equity Grant Panel

28. Reviewer recommendation

Applicants must suggest the names of at least 3 (5 if submitting application in French) impartial reviewers who have the necessary expertise to critically evaluate the application and with whom you do NOT collaborate.

Name	Department	Institution	Phone no.	E-mail address	Areas of expertise

29. Reviewer exclusions

Applicants may suggest individuals they prefer NOT be contacted as potential reviewers (panel members and/or external reviewers). The reason for exclusion (e.g. collaborator, colleague, competitor) should be given. NOTE: any exclusions you list will not be viewable to panel members.

Name	Reason for exclusion

Tracking

30. Research tracking information

30.a. CCS Research Goals

Select the CCS Research Goal(s) that will be addressed by your proposed research. Select all that apply.

- ☐ Prevention - fewer people in Canada will develop cancer
- ☐ Early diagnosis - fewer people will be diagnosed with cancer at stage III or IV
- ☐ Treatment and quality of life - people with cancer will live longer and with an improved quality of life during and after treatment
- ☐ Equitable and timely access to care - more people in Canada will have equitable and timely access to innovative and affordable high quality cancer care

CCS Research Goal (distribution)	Percentage

30.b. Research focus

Responses are to be limited to the scope of the proposed research for the duration of the proposed term. This information is used solely for statistical/reporting purposes and will not be used as part of the scientific review of the application. Select one research focus that best describes the project.

Biomedical research – Projects that rely on model systems or are basic/fundamental research. Includes understanding disease mechanisms or studying cell pathways in model systems or patient-derived cell lines. If any component of the project uses patient-derived tissue or involves human subjects, it should be coded as clinical research.

Clinical research – Projects that have a component that is clinical and/or involves human subjects. Includes companion clinical trials and correlative studies as well as psychosocial oncology research. Generally, involves humans or samples from humans. Includes testing drugs, biomarkers, or mechanism of action of drugs in patients, patient-derived tumours, or liquid biopsies.

Health systems and health services research - Research that assesses or attempts to solve barriers to care, treatment adherence, care utilization, overtreatment, health care transitions, national strategies/frameworks, clinical pathways/guidelines, ethics, patient decision aids, adverse drug reactions, treatment delays/wait times, access/equity, and/or health literacy.

Social, cultural, environmental, and population health research – Research that is population-level and unrelated to the health system. Includes research that investigates lifestyle, toxin exposures, diet, or population-based surveillance surveys (e.g., the International Tobacco Control (ITC) survey, British Columbia Adolescent Substance Use Survey).

Research focus (select ONE only)

- ○ Biomedical Research
- ○ Clinical Research
- ○ Health Services/Systems Research
- ○ Social, Cultural, Environmental and Population Health

30.c. Clinical trial

If your proposed research includes a clinical trial component, select the type of trial and provide the participant recruitment target. If your proposed research does not involve a clinical trial, select not applicable.

- ☐ Clinical Trial - observational participant recruitment target:
- ☐ Clinical Trial - interventional participant recruitment target:
- ☐ Not applicable

30.d. Relevant cancer population

Select the cancer population(s) the proposed research is focused on and will be relevant to. If your proposed research can be applied broadly to cancer patients, select “Not specific”. Be sure to select at least one item. Note: Only select pediatric or AYA populations if the research is specific to these populations.

- ☐ Pediatric (0-14) - only select if specific to pediatric cancer population
- ☐ Adolescents and young adults (15-39) - only select if specific to and focused on AYA cancer population. It is not sufficient to be encompassing of the AYA age range
- ☐ Adult (18+)
- ☐ Not specific

30.e. Underserved populations

Please indicate if your research project specifically addresses cancer in one of the following populations. Select only those that apply. If your proposed research does not focus on one of these populations, select “Not applicable”.

- ☐ Black
- ☐ Immigrant
- ☐ First Nations, Indigenous, Metis
- ☐ LGBTQ2S+
- ☐ Other:
- ☐ Not applicable

30.f. Research subject

If your proposed research involves human subjects or patient tissues, select the research subject(s) that will be used in the study. You can select more than one option. If your proposed research does not involve human subjects or patient tissues, select “Not applicable”.

Patients/Study Population

- ☐ Pediatric (0-14)
- ☐ Adolescents and young adults (15-39)
- ☐ Adult (18+)
- ☐ Not applicable

Patient Tissue

- ☐ Pediatric (0-14)
- ☐ Adolescents and young adults (15-39)
- ☐ Adult (18+)
- ☐ Not applicable

30.g. Cancer site relevance

Select a maximum of four cancer sites where the research will be most relevant. Indicate the degree of relevance to the selected cancer site in terms of percentage (%). Only include cancer sites with at least 25% relevance; total should equal 100%.
The cancer site selected must reflect the site of the primary cancer. For example, if your research is focused on lung cancer that has metastasized to the brain, select lung as relevant cancer site. When a project does not focus on one or more specific cancer sites (e.g. applies broadly to cancer patients), select “Non-specific/All sites”. Only use the Details description field to describe the site if you have selected Other as a site. Do not enter a ‘%’ sign with your percentage, only enter the number.

Select a maximum of four cancer sites where the research will be most relevant.

Cancer site	Percentage	Details

30.h. Common Scientific Outline (CSO)

Select a maximum of 3 codes which best describe the research. Full details of the Common Scientific Outline can be found at the International Cancer Research Portfolio website (https://www.icrpartnership.org/cso).

Biology

- ☐ 1.1 Normal functioning
- ☐ 1.2 Cancer initiation: alterations in chromosomes
- ☐ 1.3 Cancer initiation: oncogenes and tumour suppressor genes
- ☐ 1.4 Cancer progression and metastasis
- ☐ 1.5 Resources and infrastructure

Etiology

- ☐ 2.1 Exogenous factors in the origin and cause of cancer
- ☐ 2.2 Endogenous factors in the origin and cause of cancer
- ☐ 2.3 Interactions of genes and/or genetic polymorphisms with exogenous and/or endogenous factors
- ☐ 2.4 Resources and infrastructure related to etiology

Prevention

- ☐ 3.1 Interventions to prevent cancer: personal behaviors (non-dietary) that affect cancer risk
- ☐ 3.2 Dietary interventions to reduce cancer risk and nutritional science in cancer prevention
- ☐ 3.3 Chemoprevention and other medical interventions
- ☐ 3.4 Preventative vaccines
- ☐ 3.5 Complementary and alternative prevention approaches
- ☐ 3.6 Resources and infrastructure related to prevention

Early Detection, Diagnosis and Prognosis

- ☐ 4.1 Technology development and/or marker discovery
- ☐ 4.2 Technology and/or marker evaluation with respect to fundamental parameters of method
- ☐ 4.3 Technology and/or marker testing in a clinical setting
- ☐ 4.4 Resources and infrastructure related to detection, diagnosis and prognosis

Treatment

- ☐ 5.1 Localized therapies – discovery and development
- ☐ 5.2 Localized therapies – clinical applications
- ☐ 5.3 Systemic therapies – discovery and development
- ☐ 5.4 Systemic therapies – clinical applications
- ☐ 5.5 Combinations of localized and systemic therapies
- ☐ 5.6 Complementary and alternative treatment approaches
- ☐ 5.7 Resources and infrastructure related to treatment and the prevention of recurrence

Cancer Control, Survivorship and Outcomes Research

- ☐ 6.1 Patient care and survivorship issues
- ☐ 6.2 Surveillance
- ☐ 6.3 Population-based behavioral factors
- ☐ 6.4 Health services, economic and health policy analyses
- ☐ 6.5 Education and communication research
- ☐ 6.6 End-of-life care
- ☐ 6.7 Research on ethics and confidentiality
- ☐ 6.8 Historical code - no longer used

☐ 6.9 Resources and infrastructure related to cancer control, survivorship and outcomes research

Release form

31. Release form

CCS depends on donor dollars to fund its grants. Applicants must declare their willingness to allow the CCS to provide minimal details of their grant to potential donors/partners. For successful investigators, the grantee must declare their understanding that the CCS will post competition results (PI, HI, title, value of grant, non-confidential abstract) on the CCS website. Lay summaries of progress and impact of the research will be shared in our internal and external reports, including press releases, social media or other communications.

On condition that:

- the specified information will be shared by CCS only with potential donors/partners and for the sole purpose of obtaining additional funding for CCS's grant competitions.
- potential donors/partners will be required to declare conflict of interest, and sign a confidentiality agreement before the specified information is released to them by CCS.
- it will be held confidential by them and not released to other parties, and will be returned to CCS or destroyed if the decision is not to fund.
- all information released may be retained by the potential donors/partners if it decides to fund the application, and may be used by the donor/partner in its funding announcements and other communications.

☐ I acknowledge the sharing of the information specified with potential donors/partners and if successful in the competition, CCS will announce the grant and may publish research impacts (described above).

Head of Department

32. Head of Department/Dean confirmation

This section can only be completed by the Head of the applicant's research department. If the project is to be carried out by the Head of the Department the application must instead be confirmed by the Dean. As the Head of Department/Dean your online acknowledgement indicates that you are aware of the contents of the application being submitted. Answer the question below, then click on Save to complete your confirmation.

*I confirm that I am aware of the contents of the application being submitted. ○ Yes ○ No

*Name of the Head of Department or Dean

*Title

*Research Institution

*Financial Institution

*Date

Executive authority - research host

33. Executive authority of the host research institution

This section can only be completed by an executive authority of the host Institution within which the research will be conducted. As the Executive Authority your online acknowledgement indicates that you have read and understood the Terms of the Host Institution/CCS Agreement. Answer the question below, then click on Save to complete your confirmation.

I confirm that I have read and understood the Host Institution / CCS Agreement and agree to abide by the terms. ○ Yes ○ No

Name of the Executive Authority - research host

Title

Research Institution

Financial Institution

Date

Executive authority - financial host

34. Executive authority of the host finance institution

This section can only be completed by an executive authority of the Institution within which the funds will be administered. As the Executive Authority your online acknowledgement indicates that you have read and understood the Terms of the Host Institution/CCS Agreement. Answer the question below, then click on Save to complete your confirmation.

I confirm that I have read and understood the Host Institution / CCS Agreement, and agree to abide by the terms. ○ Yes ○ No

Name of the Executive Authority - financial host

Title

Research Institution

Financial Institution

Date

Post submission publications

35. Post submission publications

Publication lists included in this section prior to submission will be removed. This section should only be used after you have submitted your application. Attach a PDF document of your acceptance e-mail/letter for newly accepted publications. You may update this attachment at any time after you've submitted your application, up until the panel meeting. NOTE: For the file name, use the following format [lastname_firstname_publications_yyyymmdd], where yyyymmdd is the current date.